Effect of Orlistat on Plasma Leptin Levels and Risk Factors for the Metabolic Syndrome
- 1 June 2005
- journal article
- research article
- Published by SAGE Publications in Metabolic Syndrome and Related Disorders
- Vol. 3 (2) , 122-129
Abstract
Background: The aim of this research was to assess the impact of treatment with Orlistat 120 mg three times daily on serum leptin levels, weight loss, glycemic control, and cardiovascular risk factors involved in the metabolic syndrome. Methods: A 3-month open-labeled prospective study was conducted on 40 patients with the clinical features of the metabolic syndrome divided into two groups—with and without type 2 diabetes mellitus. Twenty type 2 diabetic obese patients (group A) were studied, with BMI of 35.4 ± 0.9 kg/m2, as were 20 obese patients without diabetes (group B), with BMI of 36.2 ± 0.7 kg/m2. Weight, serum leptin levels, insulin resistance, and cardiovascular risk factors were measured at baseline and at the end of each month. Results: Patients reduced weight at 8.5 ± 2.3 kg for men and 5.7 ± 2.6 kg for women in group A against 7.9 ± 1.9 kg for men and 5.6 ± 2.0 kg for women in group B. Plasma leptin levels decreased at 4.5 ± 1.9 ng/mL for men and 1.9 ± 0.9 ng/mL for women in group A against 3.8 ± 2.0 ng/mL for men and 2.8 ± 1.4 ng/mL for women in group B. The level of insulin resistance measured with HOMA-IR decreased from 4.54 ± 2.35 to 2.69 ± 0.86 in group A against 3.98 ± 1.89 to 2.87 ± 0.93 in group B. In the lipid parameters, the highest decrease was found in triglycerides levels: 6.1 ± 2.3 mmol/L for men and 3.5 ± 2.6 mmol/L for women in group A against 2.1 ± 1.9 mmol/L for men and 1.8 ± 0.7 mmol/L for women in group B (all p < 0.05). Conclusions: Orlistat beneficially enhances weight loss, contributing to a decrease of serum leptin, insulin resistance level, and cardiovascular risk factors in both groups. An additional beneficial pleotropic effect of Orlistat could be proposed through a reduction of plasma leptin and lipid levels.Keywords
This publication has 30 references indexed in Scilit:
- Leptin and other components of the Metabolic Syndrome in Mauritius—a factor analysisInternational Journal of Obesity, 2001
- Leptin Levels in Diabetic and Nondiabetic SubjectsEndocrine, 2001
- Relation between leptin and the regulation of glucose metabolismDiabetologia, 2000
- Leptin Is a Risk Marker for First-Ever Hemorrhagic Stroke in a Population-Based CohortStroke, 1999
- Obesity-Induced HypertensionHypertension, 1999
- Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO ConsultationDiabetic Medicine, 1998
- Diabetic Dyslipidemia: Basic Mechanisms Underlying the Common Hypertriglyceridemia and Low HDL Cholesterol LevelsDiabetes, 1996
- Hyperinsulinism and Dyslipidemias as Coronary Heart Disease Risk Factors in NIDDM1993
- Role of Insulin Resistance in Human DiseaseDiabetes, 1988
- Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabeticsMetabolism, 1988